Pharmacokinetic Issues of Flexeril OTC

8/10/99


Click here to start


Table of Contents

Pharmacokinetic Issues of Flexeril OTC

Pharmacokinetic Studies

Absorption and Bioavailability

Plasma Concentration-Time Profiles

Plasma Protein Binding

Elimination of Cyclobenzaprine

Proposed Metabolic Pathway

Metabolism of Cyclobenzaprine

Elderly vs. Young

Elderly vs. Young

Hepatic Impairment Patients

Hepatic Impairment Patients

Hepatic Impairment Patients

PK Considerations in OTC Switch

PK Considerations in OTC Switch

Future Goal

PPT Slide

Plasma Concentration-Time Profiles

Mean PK Parameters

Mass Balance Study

Urinary Metabolites

Mass Balance Study

Metabolism of Cyclobenzaprine

Gender

Gender

Elderly vs. Young

Elderly vs. Young

Elderly vs. Young

Elderly - Mean PK Parameters

Elderly - Mean PK Parameters

Child-Pugh Classification

Hepatic Patients - PK Parameters

Effect of Hepatic Impairment - Male vs. Female

Km Values

Ki

Author: Sue-Chih Lee